Brazil is part of the restricted group of countries that have published the most studies on covid-19 since the beginning of the new coronavirus pandemic. As of October 17, there have been 168,546 scientific publications related to the disease worldwide. Of these, 4,029 are signed by researchers working in the country. The number puts Brazilian production in the 11th position in the world ranking. It is ahead of that produced by countries like Holland, Switzerland and Japan. The information is contained in a survey carried out by the USP Academic Information Management Agency, at the request of the Dean of Research. It uses the Dimensions platform, an international database with daily updates. According to USP's Dean of Research, Sylvio Canuto, the numbers confirm the trend of good performance in Brazilian scientific production. "Brazilian science has developed a lot. We are at a very good stage of development. In the last five years, Brazil has been appearing as the 13th country that has published the most scientific articles and research reviews", said Canuto. "This year, over a period of eight months, Brazilian researchers were able to improve their performance in the specific case of covid-19."

https://www.correiobraziliense.com.br/brasil/2020/11/4890627-brasil-e-o-11-em-total-de-estudos-sobre-covid.html

The Oswaldo Cruz Foundation launched on Tuesday, 24, an express approval process in the Brazilian Registry of Clinical Trials (ReBEC) for clinical research on COVID-19. The so-called fast track may reduce the normal approval period, from up to a few weeks, to less than 48 hours. Scientists around the world will have quick access to modeling studies already underway, avoiding rework and favoring cooperation. The objective is to shorten the time between the beginning of the research, the testing and the arrival of medicines, vaccines and other innovations to society. Fast track users will receive online support through four dedicated phone lines, using messages in free apps like Telegram or Whatsapp, or even through the chat provided by the platform. They will also be able to be answered via voice call via wi-fi, with a scheduled time per message, using the same applications. In addition to the 24-hour operating system with automated e-mail messages every day, human service will be expanded, starting earlier, at 8 am, and going until 8 pm. “Our curatorship and technology team accepted the challenge and will work in shifts to meet the demand, which today is spread around the world”, guaranteed Luiza Silva, coordinator of ReBEC and specialist in risk and crisis communication. The existing fast tracks - zika, dengue, yellow fever and malaria - and the attendance to other studies will not be interrupted. The platform has more than 3,800 approved records, all of which have been validated by the most important scientific journals in the world and open to public consultation and is the only primary record in the world in Portuguese recognized by the World Health Organization.

https://www.medicina.ufmg.br/plataforma-brasileira-acelera-registro-para-estudos-sobre-covid-19/

On March 24, the Oswaldo Cruz Foundation launched an express approval process in the Brazilian Registry of Clinical Trials (ReBEC) for clinical research on COVID-19. The so-called fast track may reduce the normal approval period, from up to a few weeks, to less than 48 hours. Scientists around the world will have quick access to modeling studies already underway, avoiding rework and favoring cooperation. The objective is to shorten the time between the beginning of the research, the testing and the arrival of medicines, vaccines and other innovations to society. Fast track users will receive online support through four dedicated phone lines, using messages in free apps like Telegram or Whatsapp, or even through the chat provided by the platform. They will also be able to be answered via voice call via wi-fi, with a scheduled time per message, using the same applications. In addition to the 24-hour operating system with automated e-mail messages every day, human service will be expanded, starting earlier, at 8 am, and going until 8 pm. “Our curatorship and technology team accepted the challenge and will work in shifts to meet the demand, which today is spread around the world”, guaranteed Luiza Silva, coordinator of ReBEC and specialist in risk and crisis communication. The existing fast tracks - zika, dengue, yellow fever and malaria - and the attendance to other studies will not be interrupted. The platform has more than 3,800 approved records, all of which have been validated by the most important scientific journals in the world and open to public consultation and is the only primary record in the world in Portuguese recognized by the World Health Organization.

ICICT/Fiocruz

https://portal.fiocruz.br/noticia/plataforma-brasileira-acelera-registro-para-estudos-sobre-covid-19

All studies that evaluate the clinical, pharmacological or side effects of drugs in humans are called clinical trials. In order to conduct these studies in Brazil, participating institutions must resort to their own Ethics Committees or partner institutions, which analyze research according to the National Ethics and Research Council (Conep) and the National Health Surveillance Agency (Anvisa). To meet national and regional information needs and provide transparency to studies, the Brazilian Registry of Clinical Trials (ReBEC) - an online platform for experimental and observational studies - disseminates various research on a specific disease or drug that is underway in Brazil, through data that does not always find space in scientific journals. Managed by Fiocruz and publicly owned, the service has free access, free of charge for anyone who wants to register or consult approved records.

Adriana Martins

https://portal.fiocruz.br/noticia/rebec-plataforma-line-divulga-pesquisas-e-ensaios-clinicos-feitos-no-brasil

Scientists from national institutions have announced the creation of a mouthwash formula capable of inactivating 96% of the proliferation of the new coronavirus (Sars-CoV-2) in the upper airways. The formula is based on Phtalox technology, a compound initially created to treat bad breath and improve gum health, revealed the magazine Galileu. The study was carried out by four public institutions - USP School of Dentistry (FOB) in Bauru (SP), USP Biological Sciences Institute, State University of Londrina (PR) and Federal Institute of Paraná, in partnership with the Research Center and Innovation at DentalClean.

MARCELO DE VALÉCIO

https://www.ictq.com.br/farmacia-clinica/2327-pesquisadores-brasileiros-criam-antisseptico-bucal-que-inativa-coronavirus